论文信息 - Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience - 字舞流文

Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience

A. Tefferi | A. Pardanani | K. Begna | C. Hanson | S. Schwager | A. Abdelatif

[1] A. Jones,et al. JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug , 2013, Haematologica.

[2] T. Barbui,et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. , 2005 .

[3] I. Brodsky. Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET) , 1998, American journal of clinical oncology.

[4] Y. Najean,et al. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. , 1997, Blood.

[5] H. Heimpel,et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. , 1993, Blood.

[6] J. Goldberg,et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. , 1986, Seminars in hematology.

[7] European Organization for Research on Treatment of Cancer “Leukemia and Hematosarcoma” Cooperative G,et al. Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). , 1981, British Journal of Cancer.